Show simple item record

dc.contributor.authorMugweru, Julius
dc.contributor.authorLiu, Jianxiong
dc.contributor.authorMakafe, Gaelle
dc.contributor.authorChiwala, Gift
dc.contributor.authorWang, Bangxing
dc.contributor.authorWang, Changwei
dc.contributor.authorLi, Xinjie
dc.contributor.authorTan, Yaoju
dc.contributor.authorYew, Wing Wai
dc.contributor.authorTan, Shouyong
dc.contributor.authorZhang, Tianyu
dc.date.accessioned2018-06-13T12:57:03Z
dc.date.available2018-06-13T12:57:03Z
dc.date.issued2018-06
dc.identifier.citationInfection and Drug Resistance 2018:11 891–894en_US
dc.identifier.urihttp://hdl.handle.net/123456789/1527
dc.description.abstractEthionamide (ETA) and prothionamide (PRO) are interchangeably used in tuberculosis (TB) chemotherapy regimens. Subtle discrepancies between biochemical and genetic information on the modes of sensitivity and resistance of isoniazid (INH) and ETA warrants further studies. We report a new mutation – EthAW21R – in Mycobacterium bovis Bacillus Calmette-Guérin that corresponds with co-resistance to both PRO and ETA, which to the best of our knowledge has not been reported before. Our findings suggest that mutation EthAW21R could be used as a marker site for testing PRO and ETA cross-resistanceen_US
dc.language.isoenen_US
dc.publisherDove Pressen_US
dc.subjectmutationen_US
dc.subjectEthAW21Ren_US
dc.subjectisoniaziden_US
dc.subjectco-resistanceen_US
dc.subjectthioamidesen_US
dc.subjectmolecular markeren_US
dc.titleMutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rven_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record